[,] Since 2016, GLP-1RAs, approved for type 2 diabetes mellitus (T2DM) and obesity, have also shown cardiovascular safety
They have the right credentials and work immediately
Signos y sntomas comunes Falta de fuerza muscular cansancio y fatiga persistentes Niveles bajos de azcar en la sangre En casos extremos, pueden producirse complicaciones cardacas o hepticas
Future research should explore long-term safety, efficacy in combination with SGLT2 inhibitors, and the role of multi-agonist therapies targeting GIP, glucagon, or amylin pathways
Legal limits on BAC, such as the 0.05% limit in Australia, are enforced to ensure individuals remain sober enough to perform tasks without putting themselves or others at risk